Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Conditions:   Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified November 2016

http://ift.tt/2f8LOkB